Design, synthesis, SAR, and molecular modeling studies of acylthiocarbamates: A novel series of potent non-nucleoside HIV-1 reverse transcriptase inhibitors structurally related to phenethylthiazolylthiourea derivatives

Journal of Medicinal Chemistry

Volumn 46, Issue 5, 2003, Pages 768-781

  Ranise, Angelo ^a   Spallarossa, Andrea ^a   Schenone, Silvia ^a   Bruno, Olga ^a   Bondavalli, Francesco ^a   Vargiu, Laura ^b   Marceddu, Tiziana ^b   Mura, Massimo ^b   La Colla, Paolo ^b   Pani, Alessandra ^b  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF CAGLIARI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EMIVIRINE; L 345516; LY 73497; N ACYLTHIOCARBAMATE DERIVATIVE; NEVIRAPINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; THIOCARBAMIC ACID DERIVATIVE; TIVIRAPINE; TROVIRDINE; UNCLASSIFIED DRUG;

ARTICLE; DRUG DESIGN; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN IMMUNODEFICIENCY VIRUS 1; MOLECULAR MODEL; X RAY CRYSTALLOGRAPHY;

CELL LINE; COMPUTER-AIDED DESIGN; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; LIGANDS; MODELS, MOLECULAR; MUTATION; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; REVERSE TRANSCRIPTASE INHIBITORS; THIAZOLES; THIOCARBAMATES; THIOUREA; VIRUS REPLICATION;

EID: 0037468526     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0209984     Document Type: Article

References (57)

1. Palella, F. J., Jr; Delaney, K. M.; Moorman, A. C.; Loveless, M. O.; Fuhrer, J.; Satten, G. A.; Aschman, D.; Holmberg, S. D. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N. Engl. J. Med. 1998, 338, 853-860.
2. De Clercq, E. Novel compounds in preclinical/early clinical development for the treatment of HIV infections. Rev. Med. Virol. 2000, 10, 255-277.
3. Vella, S.; Palmisano, L. Antiretroviral therapy: state of the HAART. Antiviral Res. 2000, 45, 1-7.
4. Lucas, G. M.; Chaisson, R. E.; Moore, R. D. Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions. Ann. Intern. Med. 1999, 13, 81-87.
5. Yerly, S.; Kaiser, L.; Race, E.; Bru, J. P.; Clavel, F.; Perrin, L. Transmission of antiretroviral-drug-resistant HIV-1 variants. Lancet 1999, 354, 729-733.
6. Siliciano, R. F. Reservoirs for HIV-1. Curr. Infect. Dis. Rep. 1999, 3, 298-304.
7. Furtado, M. R.; Callaway, D. S.; Phair, J. P.; Kunstman, K. J.; Stanton, J. L.; Macken, C. A.; Perelson, A. S.; Wolinsky, S. M. Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy. N. Engl. J. Med. 1999, 340, 1614-1622.
8. Moore, J. P.; Stevenson, M. New targets for inhibitors of HIV-1 replication. Nat. Rev. Mol. Cell Biol. 2000, 1, 40-49.
9. Katz; R. A.; Skalka, A. M. The retroviral enzymes. Annu. Rev. Biochem. 1994, 63, 133-173.
10. Vaishnav, Y. N.; Wong-Staal, F. The biochemistry of AIDS. Annu. Rev. Biochem. 1991, 60, 577-630.
11. Jonckheere, H.; Anne, J.; De Clercq, E. The HIV-1 reverse transcription (RT) process as target for RT inhibitors. Med. Res. Rev. 2000, 20, 129-154.
12. Nanni, R. G.; Ding, J.; Jacobo-Molina, A.; Hughes, S. H.; Arnold, E. Review of HIV-1 reverse transcriptase three-dimensional structure: Implication for drug design. Perspect. Drug Discovery Des. 1993, 1, 129-150.
13. Esnouf, R.; Ren, J.; Ross, C.; Jones, Y.; Stammers, D.; Stuart, D. Mechanism of inhibition of HIV-1 reverse transcriptase by non-nucleoside inhibitors. Nat. Struct. Biol. 1995, 2, 303-308.
14. Richman, D.; Smith, C. K.; Lowy, I.; Rose, J.; Prodanovich, P.; Goff. S.; Griffin, J. Human Immunodeficiency Virus Type 1 Mutants Resistant to Nonnucleoside Inhibitors of Reverse Transcriptase Arise in Tissue Culture. Proc. Natl. Acad. Sci. U.S.A. 1991, 88, 11241-11245.
15. Richman, D.; D.; Havlir, D.; Corbeil, J.; Looney, D.; Ignacio, C.; Spector, S. A.; Sullivan, J.; Cheeseman, S.; Barringer, K.; Pauletti, D. Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy J. Virol. 1994, 68, 1660-1666.
16. Smerdon, S. J.; Jager, J.; Wang, J.; Kohlstaedt, L. A.; Chirino, A. J.; Friedman, J. M.; Rice, P. A.; Steitz, T. A. Structure of the binding site for nonnucleoside inhibitors of the reverse transcriptase of human immunodeficiency virus type 1. Proc. Natl. Acad. Sci. U.S.A. 1994, 91, 3911-3915.
17. Tantillo, C.; Ding, J.; Jacobo-Molina, A.; Nanni, R. G.; Boyer, P. L.; Hughes, S. H.; Pauwels, R.; Andries, K.; Janssen, P. A.; Arnold, E. Locations of anti-AIDS drug binding sites and resistance mutations in the three-dimensional structure of HIV-1 reverse transcriptase. Implications for mechanisms of drug inhibition and resistance. J. Mol. Biol. 1994, 243, 369-387.
18. Pedersen, O. S., Pedersen, E. B. The flourishing synthesis of nonnucleotide reverse transcriptase inhibitors. Synthesis 2000, 4, 479-495.
19. Ahgren, C.; Backro, K.; Bell, F. W.; Cantrell, A. S.; Clemens, M.; Colacino, J. M.; Deeter, J. B.; Engelhardt, J. A.; Hogberg, M.; Jaskunas, S. R.; Johansson, N. G.; Jordan, C. L.; Kasher, J. S.; Kinnick, M. D.; Lind, P.; Lopez, C.; Morin, J. M. Jr.; Muesing, M. A.; Noreen, R.; Oberg, B.; Paget, C. J.; Palkowitz, J. A.; Parrish, C. A.; Pranc, P.; Rippy, M. K.; Rydergard, C.; Sahlberg, C.; Swanson, S.; Ternansky, R. J.; Unge, T.; Vasileff, R. T.; Vrang, L.; West, S. J.; Zhang, H.; Zhou, X.-X. The PETT series, a new class of potent nonnucleoside inhibitors of human immunodeficiency virus type 1 reverse transcriptase. Antimicrob. Agents Chemother. 1995, 39, 1329-1335.
20. Bell, F. W.; Cantrell, A. S.; Hogberg, M.; Jaskunas, S. R.; Johansson, N. G.; Jordan, C. L.; Kinnick, M. D.; Lind, P.; Morin, J. M. Jr.; Noreen, R.; Oberg, B.; Palkowitz, J. A.; Parrish, C. A.; Pranc, P.; Sahlberg, C.; Ternansky, R. J.; Vasileff; R. T.; Vrang, L.; West, S. J.; Zhang, H.; Zhou, X.-X.PETT compounds, a new class of HIV- 1 reverse transcriptase inhibitors. 1. Synthesis and basic structure-activity relationship studies of PETT analogues. J. Med. Chem. 1995, 38, 4929-36.
21. Cantrell, A. S.; Engelhardt, P.; Hogberg, M.; Jaskunas, S. R.; Johansson, N. G.; Jordan, C. L.; Kangasmetsa, J.; Kinnick, M. D.; Lind, P.; Morin, J. M. Jr.; Muesing, M. A.; Noreen, R.; Oberg, B.; Pranc, P.; Sahlberg, C.; Ternansky, R. J.; Vasileff, R. T.; Vrang, L.; West, S. J.; Zhang, H. Phenethylthiazolylthiourea (PETT) compounds as a new class of HIV-1 reverse transcriptase inhibitors. 2. Synthesis and further structure-activity relationship studies of PETT analogues. J. Med. Chem. 1996, 39, 4261-4274.
22. Kohlstaedt, L.; A.; Wang, J.; Friedman, J. M.; Rice, P. A.; Steitz, T. A. Crystal structure at 3.5 A resolution of HIV-1 reverse transcriptase complexed with an inhibitor. Science 1992, 256, 1783-90.
23. Ren, J.; Esnouf, R.; Garman, E.; Somers, D.; Ross, C.; Kirby, I.; Keeling, J.; Darby, G.; Jones, Y.; Stuart, D.; Stammers, D. High-resolution structures of HIV-1 RT from four RT-inhibitor complexes. Nat. Struct. Biol. 1995, 2, 293-302.
24. Schafer, W.; Friebe, W. G.; Leinert, H.; Mertens, A.; Poll, T.; von der Saal, W.; Zilch, H.; Nuber, B.; Ziegler, M. L. Nonnucleoside inhibitors of HIV-1 reverse transcriptase: molecular modeling and X-ray structure investigations. J. Med. Chem. 1993, 36, 726-732.
25. Ren, J.; Esnouf, R.; Hopkins, A.; Ross, C.; Jones, Y.; Stammers, D.; Stuart, D. The structure of HIV-1 reverse transcriptase complexed with 9-chloro-TIBO: lessons for inhibitor design. Structure 1995, 3, 915-926.
26. Ding, J.; Das, K.; Tantillo, C.; Zhang, W.; Clark, A. D. J.; Jessen, S.; Lu, V.; Hsiou, Y.; Jacobo-Molina, A.; Andries, K.; Pauwels, R.; Moereels, H.; Koymans, L.; Janssen, P. A. J.; Smith, R. H. J.; Kroeger Koepke, M.; Michejda, C. J.; Hughes, S. H.; Arnold, E. Structure of HIV-1 reverse transcriptase in a complex with the non-nucleoside inhibitor alpha-APA R 95845 at 2.8 Å resolution. Structure 1995, 3, 365-379.
27. Hopkins, A. L.; Ren, J.; Esnouf, R. M.; Willcox, B. E.; Jones, E. Y.; Ross, C.; Miyasaka, T.; Walker, R. T.; Tanaka, H.; Stammers, D. K.; Stuart, D. I. Complexes of HIV-1 reverse transcriptase with inhibitors of the HEPT series reveal conformational changes relevant to the design of potent nonnucleoside inhibitors. J. Med. Chem. 1996, 39, 1589-1600.
28. Ren, J.; Esnouf, R. M.; Hopkins, A. L.; Warren, J.; Balzarini, J.; Stuart, D. I.; Stammers, D. K. Crystal structures of HIV-1 reverse transcriptase in complex with carboxanilide derivatives. Biochemistry. 1998, 37, 14394-14403.
29. Hopkins, A. L.; Ren, J.; Tanaka, H.; Baba, M.; Okamato, M.; Stuart, D. I.; Stammers, D. K. Design of MKC-442 (emivirine) analogues with improved activity against drug-resistant HIV mutants. J. Med. Chem. 1999, 42, 4500-4505.
30. Ren, J.; Esnouf, R. M.; Hopkins, A. L.; Stuart, D. I.; Stammers, D. K. Crystallographic analysis of the binding modes of thiazoloisoindolinone nonnucleoside inhibitors to HIV-1 reverse transcriptase and comparison with modeling studies. J. Med. Chem. 1999, 42, 3845-3851.
31. Ren, J.; Diprose, J.; Warren, J.; Esnouf, R. M.; Bird, L. E.; Ikemizu, S.; Slater, M.; Milton, J.; Balzarini, J.; Stuart, D. I.; Stammers, D. K. Phenylethylthiazolylthiourea (PETT) nonnucleoside inhibitors of HIV-1 and HIV-2 reverse transcriptases. Structural and biochemical analyses. J. Biol. Chem. 2000, 275, 5633-5639.
32. A preliminar account of this synthetic methodology was presented at the II Italian-Spanish joint meeting of Medicinal Chemistry, Ferrara, Italy, August 1995. Poster 115.
33. A preliminar account of anti-HIV activity of O-(2-phenoxyethyl-N-acyl-N-phenylthiocarbamates was presented at the Italian-Hungarian-Polish joint meeting on Medicinal Chemistry Taormina, Italy, September 1999. Poster 50.
34. Van Derpoorten, K.; Balzarini, J.; De Clercq, E.; Poupaert, J. H. Anti-HIV activity of N-1-adamantyl-4-aminophthalimide. Biomed. Pharmacother. 1997, 51, 464-468.
35. Vamecq, J.; Van derpoorten, K.; Poupaert, J. H.; Balzarini, J.; De Clercq, E.; Stables, J. P. Anticonvulsant phenytoinergic pharmacophores and anti-HIV activity-preliminary evidence for the dual requirement of the 4-aminophthalimide platform and the N-(1-adamantyl) substitution for antiviral properties. Life Sci. 1998, 63, 267-274.
36. Kolocouris, N.; Foscolos, G. B.; Kolocouris, A.; Marakos, P.; Pouli, N.; Fytas, G.; Ikeda, S.; De Clercq, E. Synthesis and antiviral activity evaluation of some aminoadamantane derivatives. J. Med. Chem. 1994, 37, 2896-2902.
37. Goldman, M. E. Discovery and Development of 2-Pyridinone HIV-1 Reverse Transcriptase in The Search for antiviral Drugs. Case Histories from Concept to Clinic; Adams, J., Merluzzi, V. J., Eds.; Birkhäuser: Boston, 1993; p 105.
38. Campiani, G.; Fabbrini, M.; Morelli, E.; Nacci, V.; Greco, G.; Novellino, E.; Maga, G.; Spadari, S.; Bergamini, A.; Faggioli, E.; Uccella, I.; Bolacchi, F.; Marini, S.; Coletta, M.; Fracasso, C.; Caccia, S. Non-nucleoside HIV-1 reverse transcriptase inhibitors: synthesis and biological evaluation of novel quinoxalinylethylpyridylthioureas as potent antiviral agents. Antivir. Chem. Chemother. 2000, 11, 141-155.
39. Walter, W.; Bode, K. D. Syntheses of thiocarbamates. Angew. Chem., Internat. Edit. 1967, 6, 281-384.
40. Smith, B. M.; March, J. Elimination. In March's Advanced Organic Chemistry, 5th ed.; John Wiley & Sons Inc: New York, 2001; p 1338.
41. Pearson, R. G. Hard and soft acids and bases. J. Am. Chem. Soc. 1963, 85, 3533-3539.
42. Pearson, R. G. Chemical hardness and bond dissociation energies. J. Am. Chem. Soc. 1988, 110, 7684-7690.
43. Ranise, A.; Bruno, O.; Bondavalli, F.; Schenone, S.; D'Amico, M.; Falciani, M.; Filippelli, W.; Rossi, F. 5-Substituted 2,3-dihydro-6-mercapto-1,3-diphenyl-2-thioxo-4(3H)-pyrimidinones and their 6-(acylthio) derivatives with platelet antiaggregating, antiinflammatory, antiarrhythmic, antihyperlipidemic and other activities. Farmaco 1994, 49, 551-558.
44. Ranise, A.; Bondavalli, F.; Bruno, O.; Schenone, S.; Losasso, C.; Costantino, M.; Cenicola, M. L.; Donnoli, D.; Marmo, E. 3,3-disubstituted 1-acyl-l-phenylthioureas with platelet antiaggregating and other activities. Farmaco 1991, 46, 317-338.
45. 1H NMR spectra of acylated ureas and thioureas. Coll. Czech. Chem. Commun. 1987, 52, 2474-2481.
46. Maass, G.; Immendoerfer, U.; Koenig, B.; Leser, U.; Mueller, B.; Goody, R.; Pfaff, E. Viral resistance to the thiazolo-iso-indolinones, a new class of nonnucleoside inhibitors of human immunodeficiency virus type 1 reverse transcriptase. Antimicrob. Agents Chemother. 1993, 37, 2612-2617.
47. Motakis, D.; Parniak, M. A. A Tight-Binding Mode of Inhibition Essential for Anti-Human Immunodeficiency Virus Type 1 Virucidal Activity of Nonnucleoside Reverse Transcriptase Inhibitors. Antimicrobial Agents Chemother. 2002, 46, 1851-1856.
48. Das, K.; Ding, J.; Hsiou, Y.; Clark, A. D. J.; Moereels, H.; Koymans, L.; Andries, K.; Pauwels, R.; Janssen, P. A.; Boyer, P. L.; Clark, P.; Smith, R. H. J.; Kroeger Smith, M. B.; Michejda, C. J.; Hughes, S. H.; Arnold, E. Crystal structures of 8-Cl and 9-Cl TIBO complexed with wild-type HIV-1 RT and 8-Cl TIBO complexed with the Tyr181Cys HIV-1 RT drug-resistant mutant. J. Mol. Biol. 1996, 264, 1085-100.
49. Casimiro-Garcia, A.; Micklatcher, M.; Turpin, J. A.; Stup, T. L.; Watson, K.; Buckheit, R. W.; Cushman, M. Novel modifications in the alkenyldiarylmethane (ADAM) series of non-nucleoside reverse transcriptase inhibitors. J. Med. Chem. 1999, 42, 4861-4874.
50. MacroModel Version 5.5, Columbia University, New York, 1996.
51. AM1-MOPAC: QCPE-Program No 455, Version 6.0, Quantum Chemistry Program Exchange, Indiana University, Bloomington, IN.
52. Kuntz, I. D. Structure-based strategies for drug design and discovery. Science 1992, 257, 1078-1082.
53. Dauber-Osguthorpe, P.; Roberts, V. A.; Osguthorpe, D. J.; Wolff, J.; Genest, M.; Hagler, A. T. Structure and energetics of ligand binding to proteins: Escherichia coli dihydrofolate reductase-trimethoprim, a drug-receptor system. Proteins 1988, 4, 31-47.
54. Brunger, A. T.; Adams, P. D.; Clore, G. M.; Delano, W. L.; Gros, P.; Grosse-Kunstleve, R. W.; Jiangj, S.; Kuszewski, J.; Nilges, N.; Pannu, N. S.; Read, R. J.; Rice, L. M.; Simonson T.; Warren, G. L. Crystallography and NMR system (CNS): a new software system for macromolecular structure determination. Acta Crystallogr. 1998, D54, 905-921.
55. Pauwels, R.; Balzarini, J.; Baba, M.; Snoeck, R.; Schols, D.; Herdewijn, P.; Desmyter, J.; De Clercq, E. Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds. J. Virol. Methods 1988, 20, 309-321.
56. Artico, M.; Silvestri, R.; Massa, S.; Loi, A. G.; Corrias, S.; Piras, G.; La Colla, P. 2-Sulfonyl-4-chloroanilino Moiety: A Potent Pharmacophore for the anti-Human Immunodeficiency Virus Type 1 Activity of Pyrrolyl Aryl Sulfones. J. Med. Chem. 1996, 39, 522-530.
57. Mellors, J. W.; Dutschman, G. E.; Im, G.-J.; Tramontano, E.; Winkler, S. R.; Cheng, Y.-C. In vitro Selection and Molecular Characterization of Human Immunodeficiency Virus-1 Resistant to Non-nucleoside Inhibitors of Reverse Transcriptase. Mol. Pharmacol. 1991, 42, 446-451.